These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38610806)

  • 1. Contrast-Induced Acute Kidney Injury in Patients with Heart Failure on Sodium-Glucose Cotransporter-2 Inhibitors Undergoing Radiocontrast Agent Invasive Procedures: A Propensity-Matched Analysis.
    Nardi G; Marchi E; Allinovi M; Lugli G; Biagiotti L; Di Muro FM; Valenti R; Muraca I; Tomberli B; Ciardetti N; Alterini B; Meucci F; Di Mario C; Mattesini A
    J Clin Med; 2024 Apr; 13(7):. PubMed ID: 38610806
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute Kidney Injury Events in Patients With Type 2 Diabetes Using SGLT2 Inhibitors Versus Other Glucose-Lowering Drugs: A Retrospective Cohort Study.
    Rampersad C; Kraut E; Whitlock RH; Komenda P; Woo V; Rigatto C; Tangri N
    Am J Kidney Dis; 2020 Oct; 76(4):471-479.e1. PubMed ID: 32464161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contrast-Induced Acute Kidney Injury in Patients on SGLT2 Inhibitors Undergoing Percutaneous Coronary Interventions: A Propensity-Matched Analysis.
    Hua R; Ding N; Guo H; Wu Y; Yuan Z; Li T
    Front Cardiovasc Med; 2022; 9():918167. PubMed ID: 35795364
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M; Paik JM; Wexler DJ; Bonventre JV; Kim SC; Patorno E
    Am J Kidney Dis; 2022 Jun; 79(6):858-867.e1. PubMed ID: 34762974
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of SGLT2 inhibitor dapagliflozin with risks of acute kidney injury and all-cause mortality in acute myocardial infarction patients.
    Cai D; Chen Q; Mao L; Xiao T; Wang Y; Gu Q; Wang Q; Ji Y; Sun L
    Eur J Clin Pharmacol; 2024 Apr; 80(4):613-620. PubMed ID: 38319348
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes in diabetic patients treated with SGLT2-Inhibitors with acute myocardial infarction undergoing PCI: The SGLT2-I AMI PROTECT Registry.
    Paolisso P; Bergamaschi L; Gragnano F; Gallinoro E; Cesaro A; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Esposito G; Morici N; Andrea OJ; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Marfella R; Calabrò P; Pizzi C; Barbato E
    Pharmacol Res; 2023 Jan; 187():106597. PubMed ID: 36470546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of sodium-glucose cotransporter-2 inhibitors and aldosterone antagonists, in addition to renin-angiotensin system antagonists, on major adverse kidney outcomes in patients with type 2 diabetes and chronic kidney disease: A systematic review and network meta-analysis.
    Yang S; Zhao L; Mi Y; He W
    Diabetes Obes Metab; 2022 Nov; 24(11):2159-2168. PubMed ID: 35712807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: Insight from SGLT2-I AMI PROTECT registry.
    Paolisso P; Bergamaschi L; Cesaro A; Gallinoro E; Gragnano F; Sardu C; Mileva N; Foà A; Armillotta M; Sansonetti A; Amicone S; Impellizzeri A; Belmonte M; Esposito G; Morici N; Andrea Oreglia J; Casella G; Mauro C; Vassilev D; Galie N; Santulli G; Calabrò P; Barbato E; Marfella R; Pizzi C
    Diabetes Res Clin Pract; 2023 Aug; 202():110766. PubMed ID: 37276980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sodium-Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Population-Based Investigation.
    Kwon O; Myong JP; Lee Y; Choi YJ; Yi JE; Seo SM; Jang SW; Kim PJ; Lee JM
    J Am Heart Assoc; 2023 Jul; 12(14):e027824. PubMed ID: 37421263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis.
    Salah HM; Al'Aref SJ; Khan MS; Al-Hawwas M; Vallurupalli S; Mehta JL; Mounsey JP; Greene SJ; McGuire DK; Lopes RD; Fudim M
    Cardiovasc Diabetol; 2022 Feb; 21(1):20. PubMed ID: 35123480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Acute Kidney Injury Following Contrast-enhanced CT in Hospitalized Pediatric Patients: A Propensity Score Analysis.
    Gilligan LA; Davenport MS; Trout AT; Su W; Zhang B; Goldstein SL; Dillman JR
    Radiology; 2020 Mar; 294(3):548-556. PubMed ID: 31961262
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential renoprotective effect of SGLT2 inhibitors against contrast-induced AKI in diabetic STEMI patients undergoing primary PCI.
    Kültürsay B; Yılmaz C; Güven B; Mutlu D; Karagöz A
    Kardiol Pol; 2024; 82(1):29-36. PubMed ID: 38230461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of risk factors associated with acute kidney injury in patients taking sodium-glucose cotransporter-2 inhibitors.
    Schumacher C; Chorpash A; Bolch C; Eagan K; Nimer S; Van Dril E
    Pharmacotherapy; 2024 Mar; 44(3):249-257. PubMed ID: 38131129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lessons from a pre-specified meta-analysis of sodium-glucose cotransporter-2 (SGLT2) inhibitors in heart failure: Time for new clinical recommendations.
    Kotit S
    Glob Cardiol Sci Pract; 2023 May; 2023(2):e202314. PubMed ID: 37351098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of sodium-glucose cotransporter 2 inhibitors with cardiovascular outcome and safety events: A meta-analysis of randomized controlled clinical trials.
    Gong C; Shen SC; Zhang K; Zhou L; Shen JJ; Zhao JY; Ding SG; Ma LK; Gao H
    Front Cardiovasc Med; 2022; 9():926979. PubMed ID: 36312269
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter-2 inhibitors improve cardiovascular outcomes post-acute coronary syndrome complicated by acute heart failure.
    Rahhal A; Hamamyh T; Chapra A; Zaza KJ; Najim M; Hemadneh M; Faraj H; Kanjo W; Yasin A; Toba H; Mohammed W; Hamad MK; Al-Tikrety N; Baraa Habib M; Awaisu A; Mahfouz A; Alyafei S; Arabi AR; Patel A; Al-Hijji M
    Front Cardiovasc Med; 2024; 11():1383669. PubMed ID: 38832317
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side effects and treatment initiation barriers of sodium-glucose cotransporter 2 inhibitors in heart failure: a systematic review and meta-analysis.
    Vukadinović D; Abdin A; Anker SD; Rosano GMC; Mahfoud F; Packer M; Butler J; Böhm M
    Eur J Heart Fail; 2022 Sep; 24(9):1625-1632. PubMed ID: 35730422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of sodium-glucose cotransporter 2 inhibitors for renal prognosis and mortality in diabetes patients with heart failure on diuretics.
    Weng YF; Chen CY; Hwang SJ; Huang YB
    Kaohsiung J Med Sci; 2023 Apr; 39(4):416-425. PubMed ID: 36625282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is intravenous iodinated contrast medium administration really harmful in hospitalized acute kidney injury patients: a propensity score-matched study.
    Yan P; Zhang NY; Luo XQ; Wang M; Deng YH; Wu T; Wu X; Liu Q; Wang HS; Wang L; Kang YX; Duan SB
    Eur Radiol; 2022 Feb; 32(2):1163-1172. PubMed ID: 34342692
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Network Meta-Analysis of Novel Glucose-Lowering Drugs on Risk of Acute Kidney Injury.
    Zhao M; Sun S; Huang Z; Wang T; Tang H
    Clin J Am Soc Nephrol; 2020 Dec; 16(1):70-78. PubMed ID: 33376101
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.